This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Eli Lilly adds to argument against fine, asks Brazilian regulator to review finding of repeated infringement

By Flavia Fortes ( July 27, 2015, 21:37 GMT | Insight) -- Eli Lilly do Brasil has filed a new appeal with the Brazilian competition authority arguing against the 36.6 million reais ($11.8 million) fine imposed on the company for launching spurious court actions to block the entry of generic versions of a cancer drug in Brazil. Eli Lilly had previously asked the agency to reconsider the fine, citing omissions and contradictions in the decision, and now is asking that the finding of repeated infringement be repealed and the resulting double fine be revoked.Eli Lilly do Brasil has filed a new appeal with the Brazilian competition authority arguing against the 36.6 million reais ($11.8 million) fine imposed on the company for launching spurious court actions to block the entry of generic versions of a cancer drug in Brazil....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections